Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Recent Updates on Salivary Gland Tumors
share announcement

Recent Updates on Salivary Gland Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (12 December 2023) | Viewed by 4662

Special Issue Editors

Prof. Dr. Stephan Lang

E-Mail Website
Guest Editor
Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45122 Essen, Germany
Interests: cancer research; head and neck carcinoma
Dr. Moritz Meyer

E-Mail Website
Guest Editor
Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45122 Essen, Germany
Interests: cancer research; salivary gland carcinoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Salivary gland tumours represent a challenge in terms of diagnosis and therapy. Due to the low incidence and the diversity of histology, they remain a tumour entity in which it is necessary to establish evidence in treatment through multicentre studies. New technical and therapeutic possibilities should also be introduced in the treatment of salivary gland malignancies. Especially possibilities of digital histological image analysis could help to gain new information. One focus should be the search for new prognostically relevant biomarkers. In the therapy of salivary gland malignancies, the appropriate extent of surgical therapy and adjuvant should be explored in order to increase overall survival and, on the other hand, to maintain quality of life. The therapy of metastatic salivary gland tumours with immunotherapy and targeted therapy remains another interesting aspect to be investigated scientifically. Submissions on this topic are welcome.

Dear Colleagues,

Salivary gland tumours represent a challenge in terms of diagnosis and therapy. Due to the low incidence and the diversity of histology, they remain a tumour entity in which it is necessary to establish evidence in treatment through multicentre studies.

We are pleased to invite you to the very current topic and hopefully attract you to one of the next submissions.

Our goal is to collect submissions through the special topic from which indirect or direct improvements in the diagnosis and therapy of salivary gland malignancies will result.

This Special Issue aims to evaluate current pathological possibilities of evaluation and adapted therapeutic methods and hopefully apply them in the future to improve treatment in these diseased patients.

In particular, the possibilities of digital histological image analysis could help to gain new information. One focus should be the search for new prognostically relevant biomarkers. In the therapy of salivary gland malignancies, the appropriate extent of surgical therapy and adjuvant must be explored in order to increase overall survival and, on the other hand, to preserve the quality of life. The therapy of metastatic salivary gland tumours with immunotherapy and targeted therapy remains another interesting aspect to be investigated scientifically. Submissions on this topic are welcome.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • salivary gland carcinoma
  • therapy
  • diagnostics
  • survival
  • biomarker
  • digital imaging
  • artificial intelligence
  • immune therapy
  • targeted therapy
  • multicentre study

I look forward to receiving your contributions.

Prof. Dr. Stephan Lang
Dr. Moritz Meyer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • salivary gland carcinoma
  • therapy
  • diagnostics
  • survival
  • biomarker
  • digital imaging
  • artificial intelligence
  • immune therapy
  • targeted therapy
  • multicentre study

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1984 KiB  
Article
Novel Discovery of the Somatostatin Receptor (SSTR2) in Pleomorphic Adenomas via Immunohistochemical Analysis of Tumors of the Salivary Glands
by Felix Johnson, Benedikt Hofauer, Markus Wirth, Barbara Wollenberg, Fabian Stögbauer, Susan Notohamiprodjo, Bernhard Haller, Robin Reschke, Andreas Knopf and Ulrich Strassen
Cancers 2023, 15(15), 3917; https://doi.org/10.3390/cancers15153917 - 1 Aug 2023
Cited by 2 | Viewed by 1155
Abstract
Reliable preoperative diagnosis between salivary gland tumor entities is difficult. In this monocentric retrospective study, we examined the somatostatin receptor 2 (SSTR2) status of salivary gland tumors after salivary gland tumor resection via immunohistochemistry (IHC), and stains were compared in analogy to the [...] Read more.
Reliable preoperative diagnosis between salivary gland tumor entities is difficult. In this monocentric retrospective study, we examined the somatostatin receptor 2 (SSTR2) status of salivary gland tumors after salivary gland tumor resection via immunohistochemistry (IHC), and stains were compared in analogy to the HER2 mamma scale. A total of 42.3% of all pleomorphic adenoma (PA) tumors (42 of 99, 95% confidence interval 32.5–52.8%) demonstrated ≥20% of cells displaying the SSTR2 as compared to just 1% of all other tumors (1/160, 95% CI 0.02–3.4%). The other tumor was a neuroendocrine carcinoma. PA had a higher intensity of SSTR2 staining, with 90.9% staining ≥ an intensity of 2 (moderate). Tumors with an intensity of SSTR2 expression equal to or greater than 2 had an 89.9% likelihood of being a PA (95% CI: 82.2–95.0%, AUC: 0.928). Only one Warthin tumor demonstrated a ‘strong’ SSTR2 staining intensity. No Warthin tumor showed a percentage of cells staining for SSTR2 above ≥20%. This result demonstrates consistent and strong expression of SSTR2 in PAs as compared to Warthin tumors, which may allow physicians to utilize radioligand-somatostatin analog PET CT/MR imaging to diagnose the PA. SSTR2 positivity, if shown to be clinically relevant, may allow peptide receptor radionuclide therapy in the future. Full article
(This article belongs to the Special Issue Recent Updates on Salivary Gland Tumors)
►▼ Show Figures

Figure 1

16 pages, 2280 KiB  
Article
The Role of an MRI-Based Radiomic Signature in Predicting Malignancy of Parotid Gland Tumors
by Delia Doris Muntean, Sorin Marian Dudea, Mihaela Băciuț, Cristian Dinu, Sebastian Stoia, Carolina Solomon, Csutak Csaba, Georgeta Mihaela Rusu and Lavinia Manuela Lenghel
Cancers 2023, 15(13), 3319; https://doi.org/10.3390/cancers15133319 - 23 Jun 2023
Cited by 3 | Viewed by 1340
Abstract
The aim of this study was to assess the ability of MRI radiomic features to differentiate between benign parotid gland tumors (BPGT) and malignant parotid gland tumors (MPGT). This retrospective study included 93 patients who underwent MRI examinations of the head and neck [...] Read more.
The aim of this study was to assess the ability of MRI radiomic features to differentiate between benign parotid gland tumors (BPGT) and malignant parotid gland tumors (MPGT). This retrospective study included 93 patients who underwent MRI examinations of the head and neck region (78 patients presenting unique PGT, while 15 patients presented double PGT). A total of 108 PGT with histological confirmation were eligible for the radiomic analysis and were assigned to a training group (n = 83; 58 BPGT; 25 MPGT) and a testing group (n = 25; 16 BPGT; 9 MPGT). The radiomic features were extracted from 3D segmentations of the PGT on the T2-weighted and fat-saturated, contrast-enhanced T1-weighted images. Following feature reduction techniques, including LASSO regression analysis, a radiomic signature (RS) was built with five radiomic features. The RS presented a good diagnostic performance in differentiating between PGT, achieving an area under the curve (AUC) of 0.852 (p < 0.001) in the training set and 0.786 (p = 0.017) in the testing set. In both datasets, the RS proved to have lower values in the BPGT group as compared to MPGT group (p < 0.001 and p = 0.023, respectively). The multivariate analysis revealed that RS was independently associated with PGT malignancy, together with the ill-defined margin pattern (p = 0.031, p = 0.001, respectively). The complex model, using clinical data, MRI features and the RS, presented a higher diagnostic performance (AUC of 0.976) in comparison to the RS alone. MRI-based radiomic features could be considered potential additional imaging biomarkers able to discriminate between benign and malignant parotid gland tumors. Full article
(This article belongs to the Special Issue Recent Updates on Salivary Gland Tumors)
►▼ Show Figures

Figure 1

15 pages, 1776 KiB  
Article
Radiomic Features Associated with Lymphoma Development in the Parotid Glands of Patients with Primary Sjögren’s Syndrome
by Delia Doris Muntean, Lavinia Manuela Lenghel, Paul Andrei Ștefan, Daniela Fodor, Maria Bădărînză, Csaba Csutak, Sorin Marian Dudea and Georgeta Mihaela Rusu
Cancers 2023, 15(5), 1380; https://doi.org/10.3390/cancers15051380 - 22 Feb 2023
Cited by 1 | Viewed by 1549
Abstract
Non-Hodgkin Lymphoma (NHL) represents a severe complication and the main cause of morbidity in patients with primary Sjögren’s syndrome (pSS). This study aimed to assess the role of textural analysis (TA) in revealing lymphoma-associated imaging parameters in the parotid gland (PG) parenchyma of [...] Read more.
Non-Hodgkin Lymphoma (NHL) represents a severe complication and the main cause of morbidity in patients with primary Sjögren’s syndrome (pSS). This study aimed to assess the role of textural analysis (TA) in revealing lymphoma-associated imaging parameters in the parotid gland (PG) parenchyma of patients with pSS. This retrospective study included a total of 36 patients (54.93 ± 13.34 years old; 91.6% females) diagnosed with pSS according to the American College of Rheumatology and the European League Against Rheumatism criteria (24 subjects with pSS and no lymphomatous proliferation; 12 subjects with pSS and NHL development in the PG, confirmed by the histopathological analysis). All subjects underwent MR scanning between January 2018 and October 2022. The coronal STIR PROPELLER sequence was employed to segment PG and perform TA using the MaZda5 software. A total of 65 PGs underwent segmentation and texture feature extraction (48 PGs were included in the pSS control group, and 17 PGs were included in the pSS NHL group). Following parameter reduction techniques, univariate analysis, multivariate regression, and receiver operating characteristics (ROC) analysis, the following TA parameters proved to be independently associated with NHL development in pSS: CH4S6_Sum_Variance and CV4S6_Inverse_Difference_Moment, with an area under ROC of 0.800 and 0.875, respectively. The radiomic model (resulting by combining the two previously independent TA features), presented 94.12% sensitivity and 85.42% specificity in differentiating between the two studied groups, reaching the highest area under ROC of 0.931 for the chosen cutoff value of 1.556. This study suggests the potential role of radiomics in revealing new imaging biomarkers that might serve as useful predictors for lymphoma development in patients with pSS. Further research on multicentric cohorts is warranted to confirm the obtained results and the added benefit of TA in risk stratification for patients with pSS. Full article
(This article belongs to the Special Issue Recent Updates on Salivary Gland Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop